ArticleFrontiers in immunology2025
An assembled molecular signaling map of interleukin-24: a resource to decipher its multifunctional immunoregulatory role in pathophysiological conditions.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The dual pathogenic role of IL-24 in sepsis: Coupling bacterial dissemination with inflammatory amplification as a therapeutic target.Virulence · 2026Article
- CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Immunotherapy for tuberculosis: current strategies and future directions.Military Medical Research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Interleukin-24 (IL-24) is a cytokine belonging to the IL-10 family with immunoregulatory properties. It is known to induce cellular responses in various disease conditions, including inflammatory, infectious diseases, and cancer, in a receptor-dependent and independent manner. IL-24 is induced by both immune and non-immune cells and acts on a vast array of target cells to regulate various biological processes. The antitumor and immunoregulatory properties of IL-24 support its application as a therapeutic agent in a vast array of pathological conditions. Characterizing the molecular events associated with its immunomodulatory properties is essential for evaluating its utility in cancer immunotherapy. Methods: The data related to signaling events induced by IL-24 were then manually annotated and cataloged from the literature pertaining to IL-24 signaling. The cataloged molecular events were then manually drawn based on the topology as a signaling pathway map of IL-24. Results: Based on the data mined from published literature, we assembled IL-24-regulated signaling events linked to its immunoregulatory and anti-tumor activities. The receptor-ligand interaction of IL-24 regulates multiple downstream signaling cascades, leading to antitumor activities alongside inducing inflammatory reactions and anti-infectious processes. We provide a signaling pathway map of IL-24 consisting of 433 mRNAs/proteins and their 613 signaling events. Discussion: We believe this map would serve as a knowledge base for reference and one-go visualization of the signaling events identified to be induced by IL-24. Moreover, this map is made available (https://ciods.in/il24/) for the researchers to explore the role of IL-24 in various pathophysiological conditions through the gene set enrichment of transcriptomics or proteomics datasets from various disease conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.